FindTrial
Sign In

Refining TNM staging system for nasopharyngeal carcinoma based on Epstein-Barr virus DNA status: a multicenter retrospective cohort study

Refining TNM staging system for nasopharyngeal carcinoma based on Epstein-Barr virus DNA status: a multicenter retrospective cohort study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000041046
Enrollment
Unknown
Registered
2020-12-17
Start date
2020-12-21
Completion date
Unknown
Last updated
2021-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nasopharyngeal carcinoma

Interventions

EBV DNA(-) group vs EBV DNA(+) group:Nil

Sponsors

Sun Yat-Sen University Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Previously untreated nonmetastatic (M0) NPC; 2. histological subtype of WHO type II or III NPC; 3. positivity on EBV viral antigen; 4. treatment with curative IMRT with or without platinum-based chemotherapy; and 5. availability of data on baseline plasma EBV DNA titers.

Exclusion criteria

Exclusion criteria: The required medical record information is incomplete.

Design outcomes

Primary

MeasureTime frame
Progression-free survival;—

Secondary

MeasureTime frame
Overall survival;—

Countries

China

Contacts

Public ContactYan-Qun Xiang

Sun Yat-Sen University Cancer Center

xiangyq@sysucc.org.cn+86 18666096623

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026